---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-007529"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:15:31.972367+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Atossa Therapeutics reports FY2022 net loss of $26.96M; provides clinical updates on (Z)-endoxifen trials

## Summary
- Net loss of $26.96M ($0.21 diluted EPS) vs $20.6M loss in FY2021; operating expenses up 35% to $27.7M.
- R&D expenses rose 64% to $15.1M, driven by clinical trials for (Z)-endoxifen and AT-H201 programs.
- Cash, cash equivalents and restricted cash totaled $111M as of Dec 31, 2022, down from $136.5M a year earlier.
- Initiated Phase 2 EVANGELINE study for (Z)-endoxifen in ER+/HER2- breast cancer; first patient dosed.
- Invested $4.7M in Dynamic Cell Therapies, acquiring ~19% stake; new patent granted for enteric capsule formulation.

## SEC filing metadata
- accession: 0001437749-23-007529
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000143774923007529/0001437749-23-007529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000143774923007529/atos20230315_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-007529
- JSON: https://secwatch.observer/filing/0001437749-23-007529.json
- Plain text: https://secwatch.observer/filing/0001437749-23-007529.txt

## Key facts
- Earnings Releases
  ATOSSA THERAPEUTICS, INC. reported financial results for the fiscal year ended December 31, 2022.
  - Period: the fiscal year ended December 31, 2022
  - Result: reported results
  source text: On March 22, 2023, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the year ended December 31, 2022 financial results and a Company update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000143774923007529/0001437749-23-007529-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.